FEROZ Pharmaceuticals: Major
Health Technology
Mkt Cap
17.3B
P/E (TTM)
18.35
EPS
17.86
ROE
7.50%
Div Yield
1.00%
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | ||
|---|---|---|---|---|---|---|
| Total Revenue | 18.86B | 15.85B | 11.46B | 9.33B | 8.88B | |
| Cost of Goods Sold | -11.23B | -9.65B | -7.35B | -5.53B | -5.41B | |
| Gross Profit | 7.63B | 6.20B | 4.11B | 3.80B | 3.47B | |
| SG&A Expenses | -5.64B | -4.57B | -3.16B | -2.55B | -2.00B | |
| Depreciation | -915.61M | -517.09M | -471.85M | -420.85M | -397.99M | |
| Other Operating Expense | -70.67M | -58.65M | -122.71M | -21.16M | -22.21M | |
| Total Operating Expense | -16.94B | -14.28B | -10.63B | -8.10B | -7.43B | |
| Operating Income (EBIT) | 1.92B | 1.57B | 822.58M | 1.23B | 1.45B | |
| Interest Income | 25.35M | 12.80M | 6.85M | 13.40M | 7.29M | |
| Interest Expense | -568.46M | -670.61M | -302.47M | -93.95M | -43.67M | |
| Equity in Earnings | 0 | 0 | 0 | 0 | 0 | |
| Other Non-Operating Income | 138.99M | 144.53M | -230.25M | 80.74M | 152.23M | |
| Total Non-Operating Income | -394.05M | -463.56M | -520.87M | 4.78M | 117.19M | |
| Pre-Tax Income | 1.53B | 1.11B | 301.72M | 1.24B | 1.57B | |
| Income Tax | -603.48M | -350.89M | -5.48M | -447.13M | -277.51M | |
| Minority Interest | -145.17M | -72.33M | -24.97M | -55.36M | -115.01M | |
| Net Income | 776.54M | 683.15M | 271.27M | 734.43M | 1.17B | |
| EBITDA | 2.85B | 2.11B | 1.30B | 1.65B | 1.85B | |
| EPS (Basic) | 17.86 | 15.72 | 6.24 | 16.90 | 27.00 | |
| EPS (Diluted) | 17.86 | 15.72 | 6.24 | 16.90 | 27.00 | |
| Gross Margin | 40.45% | 39.13% | 35.84% | 40.77% | 39.11% | |
| Operating Margin | 10.18% | 9.90% | 7.18% | 13.21% | 16.32% | |
| EBITDA Margin | 15.13% | 13.30% | 11.31% | 17.72% | 20.80% | |
| Pre-Tax Margin | 8.09% | 6.98% | 2.63% | 13.26% | 17.64% | |
| Net Margin | 4.12% | 4.31% | 2.37% | 7.87% | 13.22% |